Katherine Helming Walsh
Helming KC, Wang X, Wilson BG et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014; 20(3):251–254.
Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 2014;26(3):309–317.
Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC et al. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci USA. 2013;110(25):10165–10170.
Katherine Helming Walsh, Ph.D.
Katherine Helming Walsh is a research scientist I in the Cancer Program at the Broad Institute of MIT and Harvard, working under the direction of William Hahn. She is a member of the KRAS genetics team, which is a part of the KRAS initiative at Broad Instituteaimed at identifying new therapeutic targets for KRAS mutant cancers. Her work primarily focuses on follow up from genome-wide CRISPR and shRNA screens. She joined the Broad Institute in 2015.
Walsh holds a Ph.D. in biological and biomedical sciences from Harvard Medical School, which she completed in the lab of Charles Roberts at Dana Farber studying chromatin remodeling and cancer. During her doctoral studies, she also participated in the Leder Human Biology and Translational Medicine Program. In addition, she holds a B.S. from Providence College (summa cum laude) with a major in biology and a minor in Spanish.
Contact Katherine Helming Walsh at email@example.com.